Literature DB >> 23046494

Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract.

Lene Larssen1, Asle W Medhus, Hartwig Körner, Tom Glomsaker, Taran Søberg, Dagfinn Gleditsch, Øistein Hovde, Jan K Tholfsen, Knut Skreden, Arild Nesbakken, Truls Hauge.   

Abstract

BACKGROUND: Self-expanding metal stents (SEMS) are commonly used in the palliative treatment of malignant gastrointestinal (GI) obstructions with favorable short-term outcome. Data on long-term outcome are scarce, however. AIM: To evaluate long-term outcome after palliative stent treatment of malignant GI obstruction.
METHOD: Between October 2006 and April 2008, nine Norwegian hospitals included patients treated with SEMS for malignant esophageal, gastroduodenal, biliary, and colonic obstructions. Patients were followed for at least 6 months with respect to stent patency, reinterventions, and readmissions.
RESULTS: Stent placement was technically successful in 229 of 231 (99%) and clinically successful after 1 week in 220 of 229 (96%) patients. Long-term follow-up was available for 219 patients. Of those, 72 (33%) needed reinterventions. Stent occlusions or migrations (92%) were the most common reasons. Esophageal stents required reinterventions most frequently (41%), and had a significantly (p = 0.02) shorter patency (median 152 days) compared to other locations (gastroduodenal, 256 days; colon, 276 days; biliary, 460 days). Eighty percent of reinterventions were repeated endoscopic procedures that successfully restored patency. Readmissions were required for 156 (72%) patients. Progression of the underlying cancer was the most common reason, whereas 24% were readmitted due to stent complications.
CONCLUSIONS: Long-term outcome after palliative treatment with SEMS for malignant GI and biliary obstruction shows that 70% had a patent stent until death, and that most reobstructions could be solved endoscopically. Hospital readmissions were mainly related to progression of the underlying cancer disease.

Entities:  

Mesh:

Year:  2012        PMID: 23046494     DOI: 10.3109/00365521.2012.711854

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  The clinical utility of RFA in esophageal and cardia cancer patients with severe malignant obstruction.

Authors:  Hongxin Niu; Xikun Zhang; Bin Wang; Zhao Zhou; Jian Wang; Xiangshan Yang; Tong Du
Journal:  Tumour Biol       Date:  2015-08-21

Review 2.  Pancreatic cancer-improved care achievable.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Factors associated with 30-day readmission and long-term efficacy of enteral stent placement for malignancy.

Authors:  Udayakumar Navaneethan; Sudhir Duvuru; Ramprasad Jegadeesan; Preethi G K Venkatesh; Norma G Gutierrez; Jeffrey Hammel; Ravi P Kiran; Madhusudhan R Sanaka
Journal:  Surg Endosc       Date:  2014-04       Impact factor: 4.584

Review 4.  Definition of large bowel obstruction by primary colorectal cancer: A systematic review.

Authors:  Joyce V Veld; Kim J Beek; Esther C J Consten; Frank Ter Borg; Henderik L van Westreenen; Wilhelmus A Bemelman; Jeanin E van Hooft; Pieter J Tanis
Journal:  Colorectal Dis       Date:  2021-01-15       Impact factor: 3.788

5.  Efficacy of a Multiplex Paclitaxel Emission Stent Using a Pluronic® Mixture Membrane versus a Covered Metal Stent in Malignant Biliary Obstruction: A Prospective Randomized Comparative Study.

Authors:  Sung Ill Jang; Se Joon Lee; Seok Jeong; Don Haeng Lee; Myung-Hwan Kim; Hong Jin Yoon; Dong Ki Lee
Journal:  Gut Liver       Date:  2017-07-15       Impact factor: 4.519

6.  Unintentional Long-Term Esophageal Stenting due to a Complete Response in a Patient with Stage UICC IV Adenocarcinoma of the Gastroesophageal Junction.

Authors:  Anna Paeschke; Christian Bojarski; Susanne Küpferling; Thomas Hucklenbroich; Britta Siegmund; Severin Daum
Journal:  Case Rep Gastroenterol       Date:  2016-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.